Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.

Slides:



Advertisements
Similar presentations
UGA Doctor of Pharmacy Candidate
Advertisements

The Home INR Study (THINRS): Home INR Monitoring as Effective as Clinic-Based Care AK Jacobson, MD American Heart Association 2008 Scientific Sessions:
Role of the nurse in administration and safe administration PRN medication Legal and ethical aspects of medication administration Role of the multidisciplinary.
Walsall Healthcare NHS Trust Medicines Management.
Disease State Management The Pharmacist’s Role
Drug Utilization Review (DUR)
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
UMMS CRIT Module II: Drug Therapy in the Elderly Jerry H. Gurwitz, MD Chief, Division of Geriatric Medicine University of Massachusetts Medical School.
TLCTLC TLCTLC LTCLTC LTCLTC Delaware Valley Geriatric Education Center When Wrong Things Happen with Medications: Risk and Prevention by Donna Miller,
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
AF and NOACs An UPDATE JULY 2014
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Best Practices for Safe Prescribing in Older ED Patients S. Nicole Hastings, M.D., M.H.S. 1.
Concerns in Medication Safety in Regards to the Older Adult Population Stephanie A. Ball, Taylor W. Brickley, Macey F. Davenport, Kelly L. Erexson, Emily.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
American Society of Consultant Pharmacists America’s Senior Care Pharmacists® Principles of Drug Use: Prescribing for the Elderly Thomas R. Clark, RPh,
Drug safety in the elderly EFNS Stockholm 2012 Barbro Westerholm Prof.em, Member of Swedish Parliament.
Implementation of local guideline by interactive workshop improves anticoagulation therapy and patient safety Puhakka J, Helsinki Health Centre, GP Suvanto.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
HRET/K-HEN Readmissions Race Office Hour Building a Multidisciplinary Care Transitions Team January 25, 2013.
 Definitions  Goals of automation in pharmacy  Advantages/disadvantages of automation  Application of automation to the medication use process  Clinical.
Continuous Quality Improvement Drug Utilization Evaluation.
1 Prescribing Omissions according to START and related hospital admission in geriatric patients O. Dalleur 1, A. Spinewine 2, S. Henrard 3, C. Losseau.
Prescribing Errors in General Practice The PRACtICe Study (2012) GMC Investigating Prevalence and Causes.
Pharmacists’ Expanded Scope of Practice in Canada as of Oct 2014 Source: Canadian Pharmacists Association.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Problems of Polypharmacy
DVT Prevention and Anticoagulant Management
Medication Safety and admissions avoidance: A perspective Steve Williams Consultant Pharmacist in Medicine & Medication Safety Honorary Clinical Lecturer,
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Polypharmacy May 2008 CRIT Heidi Auerbach, MD Copyright Boston University Medical Center.
Specialised Geriatric Services Heather Gilley Sharon Straus.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
Chronic Illness and Older Adults
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
Introduction.
Can Nurses Assist Older CHF Patients With Self-Care? Sallie A. Alvarez NGR 5800 American Heart Association.
Pharmacotherapy in older age. Changes in pharmacokinetics and pharmacodynamics Polymorbidity, risk of DRUG-DISEASE interactions Polypharmacy, risk of.
Overcoming the Challenges & Promoting Positive Benefits Julie Davies.
TLCTLC TLCTLC LTCLTC LTCLTC Delaware Valley Geriatric Education Center When Wrong Things Happen with Medications: Risk and Prevention by Donna Miller,
Geriatric Medicine Sensible Practice in Modern Societies Liang-Kung Chen, MD PhD FRCP Aging and Health Research Center, National Yang Ming University,
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Medication Management in the Older Patient. Older adults are more likely to have an Adverse Drug Reaction More likely to be on 5 or more medications Hazzard,
Local Enhanced Service Care bundles Dr Andy Kilpatrick, Clinical Lead.
Polypharmacy Review T. Lewis GP. Six principles of medication review Patients should have a chance to raise questions and highlight problems about their.
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
ANTICOAGULATION The objectives of this section are: To be able to write prescriptions according to local anticoagulation guidelines To know how to prescribe.
Using an EHR Template and the Beer’s List to Address Geriatric Polypharmacy Rose Family Medicine Residency Emily Gutgsell, MD Emma Bjore, MD Anna Plunkett,
Comorbidity and Multimorbidity: Measurement and Interventions Holly M. Holmes, MD, MS Dept of General Internal Medicine.
A Welsh Overview of Pharmacy and Falls Prevention
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Strategies to Modernize State Medicaid Programs, Utah’s Medicaid Transformation By Lisa V. Hulbert R.Ph. Transformation Program Manager Utah Medicaid.
Based on work of the PPRNet
POLYPHARMACY IN GERIATRIC PATIENTS Dr SHREYAS MISTRY MD, Dr MAYUR RALI MD HOFSTRA-North Shore LIJ School of Medicine Department of Family Medicine Southside.
Pharmaceutical Care Plan
What’s New in Medication Management: Focus on Older Adults and Caregivers Tuesday, April 30, :00 Noon CDT Mike Varnell, RPh, CSA (214)
Medication Safety Dr. Kanar Hidayat
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
UNT Health Clinical Pharmacist Services
New Opportunities in Medicare
Prior authorization and patient cost-sharing are least likely to be seen as effective in reducing unnecessary care. “How effective do you think each of.
Medication Safety Dr. Kanar Hidayat
Clair Huckerby Consultant Pharmacist
Presentation transcript:

Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital National Yang Ming University School of Medicine

Roman poet Ovid 43 B.C. – 17 A. D.

3.1 in in at admissions 6 during admissions 8 at discharge

Medicine has largely become the practice of drug prescribing Signs and symptoms reflexively trigger a change in pharmacologic management Non-pharmacologic interventions are often available but difficult to implement Evidence-based pharmacotherapy Limited evidence in older people, especially older people with frailty

Gurwitz J. Arch Intern Med 2004;164:

Nelson MR, et al. BMJ 2002;325:815-9.

Holmes HM, et al. Arch Intern Med 2006;166: Williams CM. Am Fam Phys 2002;66:

Is there an indication for the drug? Is the medication effective for the condition? Is the dosage correct? Are the directions correct? Are the directions practical? Are there clinically significant drug-drug interactions? Are there clinically significant drug-disease interactions? Is there unnecessary duplication with other drugs? Is the duration of therapy acceptable? Is this drug the least expensive alternative compared to others of equal utility? Holmes HM, et al. Arch Intern Med 2006;166:

Limited life expectancy A certain range of time is needed to show benefits of pharmacotherapy Example: Elderly diabetic patients should have at least 5 years to show the benefits of pharmacological therapy Constraints of care time A number of health care issues to be addressed in the late life, function and quality of life may be superior to disease treatment Goal of chronic disease management deserves re- consideration Frail older people Constraints of medication harms A significantly higher risk of adverse drug events for older patients Polypharmacy is associated with poorer quality of life and poorer health care outcomes Polypharmacy sometimes becomes common in modern health care

Tan HH, et al. Diabetes Care 2004;27:2797-9

ACEI showed no protective effect against heart failure in patients aged over 75 Anticoagulant plays no protective role in older patients with atrial fibrillation but no other risk factor against stroke in terms of quality-adjusted life expectancy

Medication Quality Indicators - Prescribing indicated medications - Avoiding inappropriate medications - Education, continuity, and documentation - Medication monitoring

Hospital indicatorsAmbulatory indicators All vulnerable older adults should not be prescribed a medication with strong anticholinergic side effects if alternatives are available If a vulnerable older adult is prescribed a new drug, THEN the prescribed drug should have a clearly defined indication documented in the chart All vulnerable older adults should not be prescribed a medication with strong anticholinergic side effects if alternatives are available If a vulnerable older adults is prescribed a new drug, THEN the patient (or caregiver) should receive education about the purpose of the new drug, how to take it, and the expected side effects or important adverse reactions

Ambulatory indicators If a vulnerable older adult is prescribed a new drug, THEN the prescribed drug should have a clearly defined indication documented in the record Every new drug that is prescribed to a vulnerable older adult on an ongoing basis for chronic medical condition should have a documentation of response to therapy within 6 months If a vulnerable older adult is newly started on a diuretic, THEN serum potassium and creatinine levels should be checked within 1 month of initiation of therapy If a vulnerable older adult is prescribed a thiazide or loop diuretic, THEN s/he should have electrolyte levels checked at least yearly

Ambulatory indicators If a vulnerable older adult is newly started on an ACE inhibitor, THEN serum potassium and creatinine levels should be checked within 1 month of the initiation of therapy If a vulnerable older adult is prescribed warfarin, THEN an INR should be determined within 4 days after initiation of therapy If a vulnerable older adult is prescribed warfarin, THEN an INR should be determined at least every six weeks y

Principles of Optimal Prescribing for Older Patients 1. Start low, go slow, but get there 2. Periodic medication review and document indications of your prescriptions 3. Avoid any agent with strong anticholinergic effect if better alternative is available 4. Periodic review of effectiveness of drugs prescribed in this age group 5. Take into considerations of older patients’ life expectancy, function, and frailty 6. Think every symptoms related to prescribed medications and medication untrial

27 Integrated

看診流程 28 Registration Internal Medicine Family Medicine Case manager CGA Geriatrician Rehabilitation Neuropsychiatry Care planning

P both < Item reduced 32.3% Dose reduced 42.4% N=43, Mean age=81.4±4.5 years, 76.7% males